Tyenne®
ACTIVE PRINCIPLE:
Tocilizumab
INDICATION:
Rheumatoid Arthritis
Cytokine release syndrome
Juvenile rheumatoid arthritis
COVID-19 virus infection
Giant cell arteritis
DATE:
21/09/2023
STATUS:
Authorized
ACTIVE PRINCIPLE:
Tocilizumab
INDICATION:
Rheumatoid Arthritis
Cytokine release syndrome
Juvenile rheumatoid arthritis
COVID-19 virus infection
Giant cell arteritis
DATE:
21/09/2023
STATUS:
Authorized